Hilleman Laboratories advances two vaccines into clinical stage
Hilleman Laboratories, a first-of-its-kind joint-venture between Merck Sharp & Dohme (MSD) and the Wellcome Trust, announced the initiation of Phase I/II clinical trial of its innovative vaccine, an oral, lyophilized, heat-stable Rotavirus vaccine, against Rotavirus disease.
[adsense:336x280:8701650588]
After successful completion of the preclinical stage and obtaining regulatory clearance, Hilleman Laboratories has initiated a clinical study to establish proof-of-concept for its heat stable Rotavirus vaccine candidate.
[adsense:468x15:2204050025]
Hilleman Laboratories also obtained regulatory clearance for its innovative oral Cholera vaccine to conduct a Phase I/II clinical study that is intended to lead to an affordable vaccine against devastating Cholera infection.